AI Longevity & Full-Body MRI Fundraising: Function, Neko

How Function Health, Neko Health, Prenuvo, Ezra, Superpower, Fountain Life, Human Longevity, Q Bio, Lindus Health, Bioage, Elysium, Tally Health.

Raising Capital for AI Longevity Clinics, Preventive Diagnostics & Full-Body MRI Consumer Health Startups

AI-driven longevity clinics, full-body-MRI, multi-cancer-early-detection MCED, preventive-diagnostics, biological-age, epigenetic-clock, continuous-wearable-monitoring, concierge-preventive-care is one of the fastest-growing consumer-health categories in 2026 — Function Health $53M A Q1-2024 Andreessen Horowitz-a16z Bio+Health-Redpoint, Founders Fund Q1-2025 → $2.5B valuation Apr-2025, 100+ biomarker panels, 200k+ members, Mark Cuban, Zac Efron cofounder-adj, Neko Health $260M B Q1-2025 General Catalyst-Lightspeed, $1.8B valuation, Daniel Ek Spotify cofounder, 70+ non-invasive sensor-body-scan, Stockholm-London-NYC-est expansion, Prenuvo $70M A Q3-2022 Felicis-True Ventures, Kim Kardashian, Paris Hilton celebrity halo, full-body-MRI 60-minute-scan, 500+ conditions, 15 US clinics, $2,500 per scan, Ezra $21M B Q1-2022 Founders Fund-Accomplice, AI-full-body-MRI, FDA-cleared Ezra Flash 30-minute-scan, $1,350 price, Amazon acquisition talks Q4-2024-rumored, Superpower $34M A Q3-2024 Forerunner-Founders Fund-Bond, Jonathan Swanson-Max Marchione, 100+ biomarker, $499/year membership, concierge-longevity-primary-care, celebrity-influencer wave, Fountain Life $200M+ raised, Tony Robbins-Peter Diamandis, concierge-preventive-full-body 4-hour visit, $19,500+ member, 8 US clinics, Human Longevity Inc HLI Craig Venter-founded, $150M+ raised, Health Nucleus, full-genome, full-body-MRI, $25k+, reverse-merger Q3-2024, Q Bio $80M B Q1-2022 Andreessen Horowitz-a16z, Gigantor whole-body-MRI 15-minute-scan, digital-twin, Lindus Health $55M B Q4-2024 Balderton-Visionaries-Peter Thiel, AI-clinical-trial-CRO, preventive-diagnostic-adj, Bioage Labs IPO Sep-2024 $198M raised → $535M market cap, azelaprag GDF-15 aging biomarker, first-longevity-biotech-IPO Q3-2024 (later Nov-2024 halt-adverse-events, Q1-2025 pipeline pivot), Elysium Health $105M+ raised Basil Capital-Morningside, NAD+ Basis, Matter, Signal, Mitopure urolithin-A, concierge-tests, Tally Health $10M seed 2023 David Sinclair-adj, TallyAge epigenetic-clock, membership, Elo Health $50M+ raised General Catalyst-Toyota-Chan Zuckerberg, Elo Smart Recovery, Smart Protein, personalized-CGM, testosterone-adj, InsideTracker Segterra $20M+, blood-biomarker, Longevity Fund-adj, Levels Health $50M B Q2-2022 a16z, CGM, Marc Andreessen, Sam Corcos, Casey Means, Calley Means White-House-Kennedy-adj Q1-2025, Nutrisense $40M+ raised, CGM, dietitian, January AI $28M+ raised, CGM, AI-glucose-prediction, Signos $47M B Q4-2022 General Catalyst-Trailhead, CGM, weight-loss, Whoop $200M F Aug-2021 SoftBank Vision Fund-2 → $3.6B, WHOOP 5.0, WHOOP MG medical-grade, LeBron James, Oura $200M D Q4-2024 Fidelity-Dexcom-adj → $5.2B valuation, Gen 4, Dexcom Stelo integration, 3M+ rings, Eight Sleep $86M C Q4-2021 Valor Equity-Founders Fund, Pod 4 Ultra, Mark Zuckerberg, Elon Musk, Anthony Robbins, plus multi-cancer-early-detection MCED wave — Grail Galleri $8B Illumina-spinoff Jun-2024, Galleri PATHFINDER 2 trial, $949 per test, Medicare-coverage-pending, Guardant Health Shield FDA-approved Jul-2024 colon-cancer blood-test $895, Medicare-coverage-pending, Freenome $290M+ raised RA Capital-Perceptive-Roche, AI-early-cancer-blood-test, colorectal, Exact Sciences Cologuard, Oncotype, Riskguard MCED, GeneDx SEMA4 $50M+, WGS-preventive-genetics, Nucleus Genomics $14M seed Q4-2024 Founders Fund-Alexis Ohanian, WGS-consumer, Bryan Johnson-Blueprint-adj, Color Health $75M E Q3-2024 General Catalyst-Nvidia, Copilot for cancer-diagnosis, Medicare-Medicaid, employer-benefit — validated by FDA 510(k), De Novo, PMA, Breakthrough Device, LDT, CLIA, CAP, HIPAA, HITRUST, SOC 2, GDPR, HIPAA-compliance, American College of Radiology ACR MRI, Radiological Society of North America RSNA, American Society of Clinical Oncology ASCO, American Heart Association AHA, American Diabetes Association ADA, American Association for Cancer Research AACR, International Longevity Alliance, NIA National Institute on Aging, NIH ITP Interventions Testing Program, Buck Institute, Salk, Scripps, Broad Institute, Mount Sinai, Mayo Clinic, Cleveland Clinic, Johns Hopkins, MSK, Dana-Farber, Fred Hutch, MD Anderson, Stanford Medicine, UCSF, Harvard Medical, Yale, Duke, University of Michigan, Karolinska, Oxford, Cambridge, Imperial, King's, UCL, Weizmann, Technion academic-anchor, strategic-corporate wellness-employer United Health Optum, Aetna, Cigna, Anthem-Elevance, Humana, Kaiser, BCBS, Guardian, Sun Life, MetLife, Prudential, Manulife-John Hancock, Allianz, Ping An, AXA, Zurich, AIG, Chubb, Nippon Life, Dai-ichi, Meiji Yasuda, Sumitomo Life, Aviva, Legal & General, Prudential UK, Standard Life, Discovery Vitality, Vitality, WHOOP Health, Oura Insurance, Peloton Corporate, Google, Meta, Amazon, Apple, Microsoft, Salesforce, Adobe, Uber, Lyft, Netflix, Disney, PwC, Deloitte, EY, KPMG, Accenture, McKinsey, BCG, Bain, JPMorgan, Goldman Sachs, Morgan Stanley, Citadel, Millennium employer-benefit posture.

Why 2026 is different

Four unlocks: (1) Function Health $2.5B valuation Apr-2025 (200k+ members $499/year 100+ biomarker), Neko Health $1.8B B Q1-2025 (Daniel Ek Spotify cofounder 70+ sensor-body-scan Stockholm-London-NYC-est), Superpower $34M A Q3-2024 (Forerunner-Founders Fund-Bond concierge-longevity-primary-care $499/year) finally proved consumer-membership, concierge-preventive-primary-care, biomarker-panel model at scale. (2) Prenuvo full-body-MRI $2,500 15 US clinics, Ezra Flash 30-min-scan $1,350 FDA-cleared (Amazon-acquisition-rumored Q4-2024), Q Bio Gigantor 15-min whole-body-MRI, digital-twin, Human Longevity Health Nucleus, Fountain Life 4-hour visit finally made AI-radiology-assisted full-body-MRI accessible, high-throughput, insurance-margin viable. (3) Grail Galleri $8B Illumina-spinoff Jun-2024, Guardant Shield FDA-approved Jul-2024 colon-cancer blood-test, Freenome, Exact Sciences, GeneDx, Nucleus Genomics, Color Health finally validated multi-cancer-early-detection MCED, liquid-biopsy, WGS-preventive-genetics with regulatory-approval, Medicare-coverage-pending. (4) Whoop 5.0, WHOOP MG medical-grade, Oura Gen 4, Dexcom Stelo integration, Levels, Nutrisense, January AI, Signos, Eight Sleep Pod 4 Ultra, Apple Watch Ultra 2, Google Pixel Watch 3 continuous-wearable-monitoring, CGM-consumer, digital-twin, AI-health-copilot finally reached commercial maturity — Whoop $3.6B (SoftBank Vision Fund-2), Oura $5.2B (Fidelity-Dexcom-adj).

Realistic capital stack

Seed $3-15M for founding physician, AI, wet-lab, first-clinic, first-membership, first-biomarker-panel, first-radiology-partnership, first-celebrity-halo, first-peer-reviewed-publication (Nucleus Genomics $14M seed Founders Fund-Alexis Ohanian, Tally Health $10M seed 2023 David Sinclair-adj). Series A/B $30-260M for first-multi-clinic, first-insurance-reimbursement, first-employer-benefit, first-FDA-clearance, first-Medicare-coverage-pending, first-strategic-partnership, first-celebrity-halo at scale (Function Health $53M A a16z Bio+Health-Redpoint, Neko Health $260M B General Catalyst-Lightspeed $1.8B, Prenuvo $70M A Felicis-True, Ezra $21M B Founders Fund-Accomplice, Superpower $34M A Forerunner-Founders Fund-Bond, Q Bio $80M B a16z, Signos $47M B General Catalyst-Trailhead, Lindus Health $55M B Balderton-Visionaries-Peter Thiel, Levels Health $50M B a16z, Color Health $75M E General Catalyst-Nvidia, Eight Sleep $86M C Valor-Founders Fund). Series C/D, growth-equity, crossover, strategic-corporate, IPO $150M-$1B+ for $150M+ ARR, retention > 80%, NRR > 110%, gross-margin > 60%, celebrity-halo, peer-reviewed-clinical-validation, Medicare-coverage, insurance-reimbursement (Whoop $200M F SoftBank-2 $3.6B, Oura $200M D Fidelity-Dexcom $5.2B, Function Health $2.5B Founders Fund Q1-2025, Human Longevity Inc HLI $150M+, reverse-merger Q3-2024, Bioage Labs IPO Sep-2024 $198M raised → $535M market cap). Non-dilutive, government: NIH NIA, NCI, NHLBI, NIDDK, NHGRI, All of Us, Precision Medicine, Cancer Moonshot 2.0, DoD SBIR/STTR, DARPA, DIU, AFWERX, STRATFI, NASA Human Research, FDA Digital Health Center of Excellence, FDA Innovation Pathway, CMS Center for Medicare Innovation, Horizon Europe €95B, EU4Health, EU Cancer Plan, UK NHS, Genomics England, UK Biobank, UKRI, MRC, Innovate UK, UK ARIA £800M, Japan AMED, Moonshot 8, Korea K-Bio, Australia MRFF, Canada CIHR, Genome Canada, SIF, Israel INCPM, Singapore A*STAR, Biopolis, UAE M42-G42, Saudi PIF, KAUST, China MOST, India ICMR.

Common failure modes

Overclaiming full-body-MRI or MCED clinical-value without peer-reviewed-publication, FDA-clearance, ACR-accreditation, CLIA, CAP, HITRUST, JAMA, NEJM, Lancet, Nature Medicine anchor — post-Grail Galleri PATHFINDER 2, Guardant Shield FDA-approved, Ezra Flash FDA-cleared, Prenuvo peer-reviewed, Function Health peer-reviewed, Levels peer-reviewed, Neko Health peer-reviewed credible-clinical bar, operators without published clinical-validation, true-positive-rate, false-positive-rate, PPV, NPV, sensitivity, specificity, downstream-clinical-action, workup-rate, biopsy-rate, confirmed-diagnosis-rate metrics face FDA, FTC-consumer-marketing, insurance-medical-necessity-denial, malpractice, patient-harm-litigation, academic-critique (USPSTF grade D, Choosing Wisely, Lown Institute overtesting-overtreatment-critique) risk, Andreessen Horowitz a16z Bio+Health, Founders Fund, Forerunner, Bond, General Catalyst, Lightspeed, Felicis, True, Accomplice diligence disqualification within 12-18 months. Underestimating incidental-finding, downstream-workup, overdiagnosis-overtreatment, false-positive-cascade cost — most full-body-MRI, MCED programs produce 5-30% incidental-findings requiring $500-10,000+ downstream-workup, biopsy, specialty-referral, anxiety, surgery, treatment-cascade (many benign) that erode LTV, trust, insurance-coverage, provider-network, Bayesian-post-test-probability communication, operators without a rigorous shared-decision-making, informed-consent, result-communication, care-navigation, downstream-workup-integration, insurance-medical-necessity-pre-authorization posture face churn, reputational-damage, regulatory-scrutiny. Ignoring unit-economics, gross-margin, CAC, payback, LTV/CAC, concierge-labor-intensity, radiologist-supply-constraint — post-Amazon-One Medical, CVS-Signify-Oak Street, Walgreens-VillageMD, Walmart Health closure Apr-2024 concierge-primary-care unit-economics-scrutiny, operators without gross-margin > 60%, CAC, payback < 12-18 months, LTV/CAC > 3, throughput-per-clinic-per-day, radiologist-read-time, AI-radiology-assist-time-savings, tech-per-radiologist-productivity posture face capital-drought, take-private-only-exit at Series B/C multiples not IPO trajectory.

Frequently asked questions

Is there room for another longevity-clinic, full-body-MRI, MCED, preventive-diagnostic, or biological-age startup vs. Function Health, Neko, Prenuvo, Ezra, Superpower, Fountain Life, Human Longevity, Q Bio, Grail, Guardant, Whoop, Oura?
Yes, at the vertical-specialty, biomarker-depth, AI-radiology, insurance-reimbursement, employer-benefit, international-market layer where consumer-national-brands don't have depth. Defensible wedges are (a) vertical-specialty depth (women's health, peri-menopause, menopause, fertility, PCOS, endometriosis, men's health, andropause, testosterone, libido, cardiovascular, coronary-calcium, carotid-intima-media, heart-attack-stroke, cancer, colorectal, breast, prostate, pancreatic, ovarian, lung, skin, brain-mental-health, Alzheimer, Parkinson, MS, depression, anxiety, PTSD, gut-microbiome, IBS, IBD, SIBO, metabolic-health, diabetes, prediabetes, insulin-resistance, fatty-liver-MASH, kidney-function, sleep, apnea, hormone, thyroid, adrenal, longevity-specific), (b) biomarker, omics, genomics, proteomics, metabolomics, microbiome, epigenomics depth (Olink Explore, SomaLogic SomaScan, Nautilus, Quantum-Si, Alamar, Encodia, Seer Proteograph, Metabolon, Chronomics, TruDiagnostic, Elysium Index, Illumina NovaSeq X, PacBio Revio, Oxford Nanopore, Element AVITI depth), (c) AI-radiology, full-body-MRI, AI-DL-segmentation, AI-radiology-copilot depth (Nvidia Clara, MONAI, BioNeMo, Aidoc, Rad AI, Rapid.ai, Viz.ai, HeartFlow, Cleerly, Elucid, Perspectum, Bunkerhill, Annalise, Lunit, Vuno, Zebra Medical-Nanox, Butterfly, Caption Health, EchoNous, GE Edison, Philips Ingenia, Siemens AI-Rad, Canon Automation, United Imaging depth), (d) insurance-reimbursement, Medicare-Medicaid, private-insurance, FSA, HSA, employer-benefit, United Health Optum, Aetna, Cigna, Anthem-Elevance, Humana, Kaiser, BCBS, Guardian, Discovery Vitality, Google, Meta, Amazon, Apple, Microsoft, Salesforce, Adobe, Uber, Netflix, Disney, PwC, Deloitte, EY, KPMG, Accenture, McKinsey, BCG, Bain, JPMorgan, Goldman, Morgan Stanley, Citadel, Millennium employer-benefit anchor, (e) international-market depth (UK NHS, Genomics England, UK Biobank, EU4Health, Horizon Europe, Japan AMED, Moonshot 8, Korea K-Bio, Australia MRFF, Canada CIHR, Genome Canada, Israel INCPM, Singapore Biopolis, UAE M42-G42, Saudi PIF, KAUST, China, India ICMR), (f) celebrity-halo, creator-partnership, Kim Kardashian, Paris Hilton, Mark Cuban, Tony Robbins, Peter Diamandis, Zac Efron, LeBron James, Cristiano Ronaldo, Andrew Huberman, Peter Attia, Bryan Johnson, Rhonda Patrick, David Sinclair, Casey Means, Calley Means, Mark Hyman, Rich Roll, Dave Asprey, Ben Greenfield, Tim Ferriss, Joe Rogan, Lex Fridman, Naval Ravikant, Balaji, Marc Andreessen, Ben Horowitz, Andrew Yang, Reid Hoffman, Sam Altman, Elon Musk, Jeff Bezos, Mark Zuckerberg, Sundar Pichai, Sergey Brin, Larry Page, Bill Gates, Warren Buffett, Ray Dalio, Chamath, David Sacks, Jason Calacanis, Balaji, Naval, Chase Coleman, Ken Griffin, Steven Cohen, Israel Englander celebrity-halo, earned-media depth.
How exposed is a longevity-clinic, full-body-MRI, MCED startup to Amazon-One Medical, Ezra rumored, CVS-Signify-Oak Street, UnitedHealth-Optum, and Apple, Alphabet, Illumina, Roche, Danaher first-party programs?
Meaningfully — Amazon $AMZN (Ezra acquisition-rumored Q4-2024, PillPack $753M 2018, One Medical $3.9B Feb-2022, Amazon Clinic, Amazon Pharmacy, Amazon Halo-earlier), CVS Health $CVS (Signify $8B Sep-2022, Oak Street $10.6B Feb-2023, Aetna, MinuteClinic), UnitedHealth-Optum $UNH (LHC $5.4B, naviHealth $2.5B, Change $13B, Optum Care, Optum Rx), Walgreens Boots $WBA (VillageMD $5.2B, Summit-CityMD $8.9B), Apple $AAPL (Apple Watch, Apple Health, Fitness+, Beddit, Tueo), Google-Alphabet $GOOG (Fitbit $2.1B 2021, Verily, Calico, DeepMind Health, One Medical partnership, Cerner-Oracle-adj, AlphaFold-adj), Meta $META (Ray-Ban, WHOOP-adj, Move-adj), Microsoft $MSFT (Nuance $19.7B 2022, DAX Copilot, Cerner-adj), Illumina $ILMN (Grail $8B spinoff Jun-2024, PacBio-adj), Roche $RHHBY (Freenome-adj, Foundation Medicine $2.4B 2018, Flatiron $1.9B 2018, Ventana, iRhythm-adj), Danaher $DHR (Cepheid $4B, Beckman, Leica, Pall, Aldevron, Precision NanoSystems, IDT, SCIEX, Molecular Devices, Radiometer), Thermo Fisher $TMO (PPD $17.4B 2021, Life Tech, Olink $3.1B Oct-2023-Aug-2024, Ion Torrent), Abbott $ABT (Alere, St. Jude, Freestyle Libre, i-STAT), Philips $PHG (BioTelemetry $2.8B 2021, Volcano, Spectranetics, BioIntelliSense-adj), GE Healthcare $GEHC (BK Medical, MIM, Caption Health), Siemens Healthineers $SHL (Varian $16.4B 2021, AI-Rad, AI-Radiology-Suite), Canon Medical, United Imaging, Bayer $BAYRY, Merck, Novartis, Pfizer, Bristol-Myers, AstraZeneca, GSK, Sanofi, Eli Lilly, Regeneron, Vertex, Amgen, Gilead, Biogen, Moderna, BioNTech, Novo Nordisk strategic-corporate, platform-roll-up, private-equity KKR, Blackstone, Bain, Advent, Carlyle, Apollo, Silver Lake, Vista, Thoma Bravo, Warburg, Hellman & Friedman, General Atlantic, Ares take-private, platform-roll-up pull. Defensible wedges are (a) vertical-specialty, biomarker, AI-radiology depth, (b) insurance-reimbursement, Medicare-Medicaid, employer-benefit anchor, (c) international-market depth (NHS, EU, AMED, K-Bio, MRFF, CIHR, Genome Canada, INCPM, A*STAR, M42-G42, PIF, KAUST, MOST, ICMR), (d) celebrity-halo, creator-partnership, earned-media, PR depth, (e) IP, composition-of-matter, trade-secret, FDA, FTC-consumer-marketing, regulatory-clarity depth, (f) sovereign-anchor PIF, Mubadala, G42, M42, GIC, Temasek, KIA, ADIA, NBIM, APG, PGGM, CDPQ, CPPIB strategic-round depth.
Realistic exit?
Amazon $AMZN, CVS Health $CVS, UnitedHealth-Optum $UNH, Walgreens Boots $WBA, Apple $AAPL, Alphabet-Google $GOOG, Meta $META, Microsoft $MSFT, Illumina $ILMN, Roche $RHHBY, Danaher $DHR, Thermo Fisher $TMO, Abbott $ABT, Boston Scientific $BSX, Medtronic $MDT, Philips $PHG, GE Healthcare $GEHC, Siemens Healthineers $SHL, Canon Medical, United Imaging, Bayer $BAYRY, Merck KGaA $MRK, Novartis $NVS, Pfizer $PFE, Bristol-Myers-Squibb $BMY, AstraZeneca $AZN, GSK $GSK, Sanofi $SNY, Eli Lilly $LLY, Regeneron $REGN, Vertex $VRTX, Amgen $AMGN, Gilead $GILD, Biogen $BIIB, Moderna $MRNA, BioNTech $BNTX, Novo Nordisk $NVO strategic-acquisition, platform-roll-up, private-equity KKR, Blackstone, Bain Capital, Advent, Carlyle, Apollo, Silver Lake, Vista, Thoma Bravo, Warburg Pincus, Hellman & Friedman, General Atlantic, Ares take-private, platform-roll-up dominate; IPO reserved for two or three category leaders at $150M+ ARR, retention > 80%, NRR > 110%, gross-margin > 60%, celebrity-halo, peer-reviewed-clinical-validation, Medicare-coverage, insurance-reimbursement anchor — Function Health, Neko Health, Prenuvo, Superpower, Whoop, Oura, Grail-Illumina, Guardant, Bioage-adj on 3-7 year IPO horizon. Recent comps: Function Health $53M A Q1-2024 a16z Bio+Health-Redpoint, Founders Fund Q1-2025 → $2.5B valuation Apr-2025 200k+ members $499/year, Neko Health $260M B Q1-2025 General Catalyst-Lightspeed → $1.8B Daniel Ek Spotify cofounder, Prenuvo $70M A Q3-2022 Felicis-True Kim Kardashian, Paris Hilton, Ezra $21M B Q1-2022 Founders Fund-Accomplice, Amazon acquisition-rumored Q4-2024, Superpower $34M A Q3-2024 Forerunner-Founders Fund-Bond, Fountain Life $200M+ Tony Robbins-Peter Diamandis, Human Longevity Inc HLI $150M+, reverse-merger Q3-2024, Q Bio $80M B Q1-2022 a16z, Lindus Health $55M B Q4-2024 Balderton-Visionaries-Peter Thiel, Bioage Labs IPO Sep-2024 $198M → $535M market cap (later Nov-2024 azelaprag halt, Q1-2025 pipeline pivot), Elysium Health $105M+ Basil-Morningside, Tally Health $10M seed 2023 David Sinclair-adj, Elo Health $50M+ General Catalyst-Toyota-CZI, Levels Health $50M B Q2-2022 a16z, Signos $47M B Q4-2022 General Catalyst-Trailhead, Whoop $200M F Aug-2021 SoftBank Vision Fund-2 → $3.6B WHOOP 5.0, WHOOP MG LeBron, Oura $200M D Q4-2024 Fidelity-Dexcom-adj → $5.2B Gen 4, Dexcom Stelo 3M+ rings, Eight Sleep $86M C Q4-2021 Valor-Founders Fund Pod 4 Ultra Zuckerberg, Musk, Robbins, Grail Galleri $8B Illumina-spinoff Jun-2024, Guardant Health Shield FDA-approved Jul-2024, Freenome $290M+ RA Capital-Perceptive-Roche, Nucleus Genomics $14M seed Q4-2024 Founders Fund-Alexis Ohanian, Color Health $75M E Q3-2024 General Catalyst-Nvidia. Most likely near-term path is Amazon, CVS, UnitedHealth-Optum, Walgreens, Apple, Alphabet, Meta, Microsoft, Illumina, Roche, Danaher, Thermo Fisher, Abbott, Boston Scientific, Medtronic, Philips, GE Healthcare, Siemens Healthineers, Canon Medical, United Imaging, Bayer, Merck, Novartis, Pfizer, Bristol-Myers, AstraZeneca, GSK, Sanofi, Eli Lilly, Regeneron, Vertex, Amgen, Gilead, Biogen, Moderna, BioNTech, Novo Nordisk strategic-acquisition, private-equity KKR, Blackstone, Bain, Advent, Carlyle, Apollo, Silver Lake, Vista, Thoma Bravo, Warburg, Hellman & Friedman, General Atlantic, Ares take-private, platform-roll-up.

Related fundraising verticals (40)

Investor directory · Fundraising library · Articles A–Z · Company funding database